Bristol-Myers has been given approval for what is touted as the first drug shown to prolong the lives of people with skin cancer melanoma, the New York Times reports.
The drug, called, Yervoy, gained approval from the U.S. Food and Drug Administration on Friday.
To learn more, read the Times story here.
Bristol-Myers has a tangential tie to the Triad. Convatec, a medical device maker with operations in Greensboro, was formerly part of Bristol-Myers.
Similar Posts:
- UNC, Childrens Hospital Boston develop iPhone app to report, receive drug safety news
- Study: Avastin as effective as Lucentis
- Study Finds Savings From Medicare’s Drug Plan Extend Beyond Cost of Meds
- Study: Medicare Part D reduces health care costs
- U.S. Campaign Aims to Combat Prescription Drug Abuse
